Abstract
Morbidity and mortality from diabetes mellitus (DM) are serious worldwide concerns. By the year 2030, the estimated number of diabetic patients will reach a staggering 439 million worldwide. Diabetes mellitus type 2 (DM2), which involves disturbances in both insulin secretion and resistance, is the most common form of diabetes and affects approximately 5 to 7% of the world's population. When a patient with DM2 cannot regulate his or her blood glucose levels through diet, weight loss, or exercise, oral medications, such as hypoglycemic agents (i.e., sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones), are crucial. Here, we discuss some physiological aspects of P2 receptors on pancreatic β-cells, which express a variety of P2 receptor isoforms. These receptors enhance glucose-dependent insulin release. In addition, we speculate on the potential of purinergic compounds as novel or additional treatments for Type 2 Diabetes mellitus.
Keywords: P2 receptors, Diabetes, Antagonists, Pancreatic B-cells
Current Diabetes Reviews
Title:Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment
Volume: 9 Issue: 3
Author(s): Paulo Anastacio Furtado Pacheco, Leonardo Gomes Braga Ferreira, Luiz Anastacio Alves and Robson Xavier Faria
Affiliation:
Keywords: P2 receptors, Diabetes, Antagonists, Pancreatic B-cells
Abstract: Morbidity and mortality from diabetes mellitus (DM) are serious worldwide concerns. By the year 2030, the estimated number of diabetic patients will reach a staggering 439 million worldwide. Diabetes mellitus type 2 (DM2), which involves disturbances in both insulin secretion and resistance, is the most common form of diabetes and affects approximately 5 to 7% of the world's population. When a patient with DM2 cannot regulate his or her blood glucose levels through diet, weight loss, or exercise, oral medications, such as hypoglycemic agents (i.e., sulphonylureas, biguanides, alpha glucosidase inhibitors and thiazolidinediones), are crucial. Here, we discuss some physiological aspects of P2 receptors on pancreatic β-cells, which express a variety of P2 receptor isoforms. These receptors enhance glucose-dependent insulin release. In addition, we speculate on the potential of purinergic compounds as novel or additional treatments for Type 2 Diabetes mellitus.
Export Options
About this article
Cite this article as:
Anastacio Furtado Pacheco Paulo, Gomes Braga Ferreira Leonardo, Anastacio Alves Luiz and Xavier Faria Robson, Modulation of P2 Receptors on Pancreatic β-cells by Agonists and Antagonists: A Molecular Target for Type 2 Diabetes Treatment, Current Diabetes Reviews 2013; 9 (3) . https://dx.doi.org/10.2174/1573399811309030004
DOI https://dx.doi.org/10.2174/1573399811309030004 |
Print ISSN 1573-3998 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6417 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Progesterone: Indications for the Prevention of Preterm Birth
Current Women`s Health Reviews From Adipose Tissue Protein Secretion to Adipopharmacology of Disease
Immunology, Endocrine & Metabolic Agents in Medicinal Chemistry (Discontinued) Nutrigenomics and its Impact on Life Style Associated Metabolic Diseases
Current Genomics Curcumin Reverts the Protein Differential Expression in the Liver of the Diabetic Obese db/db Mice
Current Proteomics Type 2 Diabetes Mellitus: New Genetic Insights will Lead to New Therapeutics
Current Genomics Simvastatin and Other HMG-CoA Reductase Inhibitors on Brain Cholesterol Levels in Alzheimers Disease
Current Alzheimer Research Kidney in Diabetes: from Organ Damage Target to Therapeutic Target
Current Drug Metabolism Roles of p38-MAPK in Insulin Resistant Heart: Evidence from Bench to Future Bedside Application
Current Pharmaceutical Design Subject Index To Volume 6
Cardiovascular & Hematological Disorders-Drug Targets Non-Systemic Drugs: A Critical Review
Current Pharmaceutical Design Patent Selections :
Recent Patents on Cardiovascular Drug Discovery Molecular Chaperone ORP150 in ER Stress–related Diseases
Current Pharmaceutical Design Interrelationships with Metabolic Syndrome, Obesity and Cardiovascular Risk
Current Vascular Pharmacology Markers of Early Vascular Ageing
Current Pharmaceutical Design Prenatal Stress Enhances Susceptibility to Allergic Diseases of Offspring
Endocrine, Metabolic & Immune Disorders - Drug Targets Nonalcoholic Fatty Liver Disease: The Pathogenetic Roles of Insulin Resistance and Adipocytokines
Current Molecular Medicine Evolution of Antipsychotic Intervention in the Schizophrenic Psychosis
Current Drug Targets Current Updates in the Medical Management of Obesity
Recent Patents on Endocrine, Metabolic & Immune Drug Discovery Raloxifene and Cardiovascular Health: Its Relationship to Lipid and Glucose Metabolism, Hemostatic and Inflammation Factors and Cardiovascular Function in Postmenopausal Women
Current Pharmaceutical Design Mastering the Treatment of Diabetes Mellitus Type 1 in Childhood and Adolescence
Current Pediatric Reviews